{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:56Z","timestamp":1787505956395,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"DOI":"10.7759\/cureus.111777","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:53:16Z","timestamp":1782798796000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the Efficacy of Pharmacological Interventions in the Prevention of Acute Mountain Sickness: A Network Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Indrani","family":"Sarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukainnya","family":"Buragohain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonmoni","family":"Lahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Meenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0096-2016","article-title":"Acute high-altitude sickness","volume":"26","author":"Luks AM","year":"2017","unstructured":"Luks AM, Swenson ER, B\u00e4rtsch P. Acute high-altitude sickness. Eur Respir Rev. 2017, 26:160096. 10.1183\/16000617.0096-2016","journal-title":"Eur Respir Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2017.0164","article-title":"The 2018 Lake Louise Acute Mountain Sickness score","volume":"19","author":"Roach RC","year":"2018","unstructured":"Roach RC, Hackett PH, Oelz O, B\u00e4rtsch P, Luks AM, MacInnis MJ, Baillie JK. The 2018 Lake Louise Acute Mountain Sickness score. High Alt Med Biol. 2018, 19:4-6. 10.1089\/ham.2017.0164","journal-title":"High Alt Med Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13591-X","article-title":"High-altitude illness","volume":"361","author":"Basnyat B","year":"2003","unstructured":"Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003, 361:1967-74. 10.1016\/S0140-6736(03)13591-X","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1214870","article-title":"Clinical practice: acute high-altitude illnesses","volume":"368","author":"B\u00e4rtsch P","year":"2013","unstructured":"B\u00e4rtsch P, Swenson ER. Clinical practice: acute high-altitude illnesses. N Engl J Med. 2013, 368:2294-302. 10.1056\/NEJMcp1214870","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107123450206","article-title":"High-altitude illness","volume":"345","author":"Hackett PH","year":"2001","unstructured":"Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001, 345:107-14. 10.1056\/NEJM200107123450206","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.wem.2019.04.006","article-title":"Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update","volume":"30","author":"Luks AM","year":"2019","unstructured":"Luks AM, Auerbach PS, Freer L, et al.. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019, 30:S3-18. 10.1016\/j.wem.2019.04.006","journal-title":"Wilderness Environ Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2011.1084","article-title":"Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis","volume":"13","author":"Kayser B","year":"2012","unstructured":"Kayser B, Dumont L, Lysakowski C, Combescure C, Haller G, Tram\u00e8r MR. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol. 2012, 13:82-92. 10.1089\/ham.2011.1084","journal-title":"High Alt Med Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00443.2015","article-title":"Pharmacology of acute mountain sickness: old drugs and newer thinking","volume":"120","author":"Swenson ER","year":"2016","unstructured":"Swenson ER. Pharmacology of acute mountain sickness: old drugs and newer thinking. J Appl Physiol (1985). 2016, 120:204-15. 10.1152\/japplphysiol.00443.2015","journal-title":"J Appl Physiol (1985)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12873-020-00329-8","article-title":"Efficacy\u00a0and safety of inhaled budesonide on prevention of acute mountain sickness during emergent ascent: a meta-analysis of randomized controlled trials","volume":"20","author":"Nepal G","year":"2020","unstructured":"Nepal G, Yadav JK, Rehrig JH, Bhandari N, Baniya S, Ghimire R, Mahotra N. Efficacy\u00a0and safety of inhaled budesonide on prevention of acute mountain sickness during emergent ascent: a meta-analysis of randomized controlled trials. BMC Emerg Med. 2020, 20:38. 10.1186\/s12873-020-00329-8","journal-title":"BMC Emerg Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti G","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012, 3:80-97. 10.1002\/jrsm.1037","journal-title":"Res Synth Methods"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker G","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012, 3:312-24. 10.1002\/jrsm.1058","journal-title":"Res Synth Methods"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell DM","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005, 331:897-900. 10.1136\/bmj.331.7521.897","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2104829","article-title":"Medical conditions and high-altitude travel","volume":"386","author":"Luks AM","year":"2022","unstructured":"Luks AM, Hackett PH. Medical conditions and high-altitude travel. N Engl J Med. 2022, 386:364-73. 10.1056\/NEJMra2104829","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-025-00634-y","article-title":"Dexamethasone for prevention of AMS, HACE, and HAPE and for limiting impairment of performance after rapid ascent to high altitude: a narrative review","volume":"12","author":"Burtscher J","year":"2025","unstructured":"Burtscher J, Gatterer H, Beidleman BA, Burtscher M. Dexamethasone for prevention of AMS, HACE, and HAPE and for limiting impairment of performance after rapid ascent to high altitude: a narrative review. Mil Med Res. 2025, 12:48. 10.1186\/s40779-025-00634-y","journal-title":"Mil Med Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/1527029041352054","article-title":"High altitude cerebral edema","volume":"5","author":"Hackett PH","year":"2004","unstructured":"Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol. 2004, 5:136-46. 10.1089\/1527029041352054","journal-title":"High Alt Med Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201108-1396OC","article-title":"Physiological risk factors for severe high-altitude illness: a prospective cohort study","volume":"185","author":"Richalet JP","year":"2012","unstructured":"Richalet JP, Larmignat P, Poitrine E, Letournel M, Canou\u00ef-Poitrine F. Physiological risk factors for severe high-altitude illness: a prospective cohort study. Am J Respir Crit Care Med. 2012, 185:192-8. 10.1164\/rccm.201108-1396OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2004.5.410","article-title":"Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up","volume":"5","author":"Gaillard S","year":"2004","unstructured":"Gaillard S, Dellasanta P, Loutan L, Kayser B. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up. High Alt Med Biol. 2004, 5:410-9. 10.1089\/ham.2004.5.410","journal-title":"High Alt Med Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2013.1030","article-title":"Is poor sleep quality at high altitude separate from acute mountain sickness? Factor structure and internal consistency of the Lake Louise Score Questionnaire","volume":"14","author":"Macinnis MJ","year":"2013","unstructured":"Macinnis MJ, Lanting SC, Rupert JL, Koehle MS. Is poor sleep quality at high altitude separate from acute mountain sickness? Factor structure and internal consistency of the Lake Louise Score Questionnaire. High Alt Med Biol. 2013, 14:334-7. 10.1089\/ham.2013.1030","journal-title":"High Alt Med Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21416-0","article-title":"Meta-Analysis With R","author":"Schwarzer G","year":"2015","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G.  Meta-Analysis With R. Springer International Publishing, Cham; 2015. 10.1007\/978-3-319-21416-0"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias S","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010, 29:932-44. 10.1002\/sim.3767","journal-title":"Stat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti G","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64:163-71. 10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani A","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012, 3:161-76. 10.1002\/jrsm.57","journal-title":"Res Synth Methods"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou A","year":"2020","unstructured":"Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020, 17:e1003082. 10.1371\/journal.pmed.1003082","journal-title":"PLoS Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.05.034","article-title":"Budesonide versus acetazolamide for prevention of acute mountain sickness","volume":"131","author":"Lipman GS","year":"2018","unstructured":"Lipman GS, Pomeranz D, Burns P, et al.. Budesonide versus acetazolamide for prevention of acute mountain sickness. Am J Med. 2018, 131:200.e9-16. 10.1016\/j.amjmed.2017.05.034","journal-title":"Am J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.wem.2023.09.002","article-title":"A randomized phase 2 study to evaluate efficacy and safety of AR36 for prevention of acute mountain sickness","volume":"34","author":"Schober A","year":"2023","unstructured":"Schober A, Chinn G, Eichbaum Y, Dudley M, Sall JW. A randomized phase 2 study to evaluate efficacy and safety of AR36 for prevention of acute mountain sickness. Wilderness Environ Med. 2023, 34:498-508. 10.1016\/j.wem.2023.09.002","journal-title":"Wilderness Environ Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.04.012","article-title":"Inhaled budesonide and oral dexamethasone prevent acute mountain sickness","volume":"127","author":"Zheng CR","year":"2014","unstructured":"Zheng CR, Chen GZ, Yu J, et al.. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. Am J Med. 2014, 127:1001-9.e2. 10.1016\/j.amjmed.2014.04.012","journal-title":"Am J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1042\/CS20030187","article-title":"Magnesium for the prevention and treatment of acute mountain sickness","volume":"106","author":"Dumont L","year":"2004","unstructured":"Dumont L, Lysakowski C, Tram\u00e8r MR, Junod JD, Mardirosoff C, Tassonyi E, Kayser B. Magnesium for the prevention and treatment of acute mountain sickness. Clin Sci (Lond). 2004, 106:269-77. 10.1042\/CS20030187","journal-title":"Clin Sci (Lond)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1055\/a-1832-0279","article-title":"Voluntary increase of minute ventilation for prevention of acute mountain sickness","volume":"43","author":"Drago S","year":"2022","unstructured":"Drago S, Campod\u00f3nico J, Sandoval M, Berendsen R, Buijze GA. Voluntary increase of minute ventilation for prevention of acute mountain sickness. Int J Sports Med. 2022, 43:971-7. 10.1055\/a-1832-0279","journal-title":"Int J Sports Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.003","article-title":"A randomized controlled trial of the lowest effective dose of acetazolamide for acute mountain sickness prevention","volume":"133","author":"Lipman GS","year":"2020","unstructured":"Lipman GS, Jurkiewicz C, Burnier A, et al.. A randomized controlled trial of the lowest effective dose of acetazolamide for acute mountain sickness prevention. Am J Med. 2020, 133:e706-15. 10.1016\/j.amjmed.2020.05.003","journal-title":"Am J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2007.1037","article-title":"Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness","volume":"9","author":"Kayser B","year":"2008","unstructured":"Kayser B, Hulsebosch R, Bosch F. Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alt Med Biol. 2008, 9:15-23. 10.1089\/ham.2007.1037","journal-title":"High Alt Med Biol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03209-7","article-title":"Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial","volume":"22","author":"Liu M","year":"2024","unstructured":"Liu M, Jiao X, Li R, et al.. Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial. BMC Med. 2024, 22:4. 10.1186\/s12916-023-03209-7","journal-title":"BMC Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.3.296","article-title":"Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial","volume":"165","author":"Chow T","year":"2005","unstructured":"Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005, 165:296-301. 10.1001\/archinte.165.3.296","journal-title":"Arch Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90937-5","article-title":"A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis","volume":"83","author":"Ellsworth AJ","year":"1987","unstructured":"Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med. 1987, 83:1024-30. 10.1016\/0002-9343(87)90937-5","journal-title":"Am J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.wem.2010.10.009","article-title":"Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group)","volume":"22","author":"Basnyat B","year":"2011","unstructured":"Basnyat B, Holck PS, Pun M, et al.. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ Med. 2011, 22:15-22. 10.1016\/j.wem.2010.10.009","journal-title":"Wilderness Environ Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2014.07.047","article-title":"Inhaled budesonide prevents acute mountain sickness in young Chinese men","volume":"48","author":"Chen GZ","year":"2015","unstructured":"Chen GZ, Zheng CR, Qin J, et al.. Inhaled budesonide prevents acute mountain sickness in young Chinese men. J Emerg Med. 2015, 48:197-206. 10.1016\/j.jemermed.2014.07.047","journal-title":"J Emerg Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21162","article-title":"Sumatriptan for prevention of acute mountain sickness: randomized clinical trial","volume":"62","author":"Jafarian S","year":"2007","unstructured":"Jafarian S, Gorouhi F, Salimi S, Lotfi J. Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Ann Neurol. 2007, 62:273-7. 10.1002\/ana.21162","journal-title":"Ann Neurol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-6-461","article-title":"Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange","volume":"116","author":"Grissom CK","year":"1992","unstructured":"Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med. 1992, 116:461-5. 10.7326\/0003-4819-116-6-461","journal-title":"Ann Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1580\/1080-6032-17.2.87","article-title":"Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial","volume":"17","author":"Hillenbrand P","year":"2006","unstructured":"Hillenbrand P, Pahari AK, Soon Y, et al.. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial. Wilderness Environ Med. 2006, 17:87-93. 10.1580\/1080-6032-17.2.87","journal-title":"Wilderness Environ Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38043.501690.7C","article-title":"Randomised, double blind, placebo controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)","volume":"328","author":"Gertsch JH","year":"2004","unstructured":"Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004, 328:797. 10.1136\/bmj.38043.501690.7C","journal-title":"BMJ"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.06.006","article-title":"Efficacy of dexamethasone in preventing acute mountain sickness in COPD patients: randomized trial","volume":"154","author":"Furian M","year":"2018","unstructured":"Furian M, Lichtblau M, Aeschbacher SS, et al.. Efficacy of dexamethasone in preventing acute mountain sickness in COPD patients: randomized trial. Chest. 2018, 154:788-97. 10.1016\/j.chest.2018.06.006","journal-title":"Chest"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1042\/CS20030188","article-title":"Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery","volume":"106","author":"Lysakowski C","year":"2004","unstructured":"Lysakowski C, Von Elm E, Dumont L, Junod JD, Tassonyi E, Kayser B, Tram\u00e8r MR. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clin Sci (Lond). 2004, 106:279-85. 10.1042\/CS20030188","journal-title":"Clin Sci (Lond)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1089\/152702901750067882","article-title":"Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude","volume":"2","author":"Bailey DM","year":"2001","unstructured":"Bailey DM, Davies B. Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol. 2001, 2:21-9. 10.1089\/152702901750067882","journal-title":"High Alt Med Biol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00806.2021","article-title":"Effects of acetazolamide on pulmonary artery pressure and prevention of high-altitude pulmonary edema after rapid active ascent to 4,559 m","volume":"132","author":"Berger MM","year":"2022","unstructured":"Berger MM, Sareban M, Schiefer LM, et al.. Effects of acetazolamide on pulmonary artery pressure and prevention of high-altitude pulmonary edema after rapid active ascent to 4,559 m. J Appl Physiol (1985). 2022, 132:1361-9. 10.1152\/japplphysiol.00806.2021","journal-title":"J Appl Physiol (1985)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.10.021","article-title":"Altitude sickness prevention with ibuprofen relative to acetazolamide","volume":"132","author":"Burns P","year":"2019","unstructured":"Burns P, Lipman GS, Warner K, et al.. Altitude sickness prevention with ibuprofen relative to acetazolamide. Am J Med. 2019, 132:247-51. 10.1016\/j.amjmed.2018.10.021","journal-title":"Am J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2008.1029","article-title":"Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness","volume":"9","author":"van Patot MC","year":"2008","unstructured":"van Patot MC, Leadbetter G 3rd, Keyes LE, Maakestad KM, Olson S, Hackett PH. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol. 2008, 9:289-93. 10.1089\/ham.2008.1029","journal-title":"High Alt Med Biol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.891182","article-title":"Effect of intravenous iron supplementation on acute mountain sickness: a preliminary randomized controlled study","volume":"21","author":"Ren X","year":"2015","unstructured":"Ren X, Zhang Q, Wang H, et al.. Effect of intravenous iron supplementation on acute mountain sickness: a preliminary randomized controlled study. Med Sci Monit. 2015, 21:2050-7. 10.12659\/MSM.891182","journal-title":"Med Sci Monit"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp026","article-title":"Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial","volume":"102","author":"Baillie JK","year":"2009","unstructured":"Baillie JK, Thompson AA, Irving JB, et al.. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM. 2009, 102:341-8. 10.1093\/qjmed\/hcp026","journal-title":"QJM"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.2.565","article-title":"The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude","volume":"127","author":"Grissom CK","year":"2005","unstructured":"Grissom CK, Richer LD, Elstad MR. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. Chest. 2005, 127:565-70. 10.1378\/chest.127.2.565","journal-title":"Chest"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2006.7.17","article-title":"Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial","volume":"7","author":"Basnyat B","year":"2006","unstructured":"Basnyat B, Gertsch JH, Holck PS, et al.. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006, 7:17-27. 10.1089\/ham.2006.7.17","journal-title":"High Alt Med Biol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1708-8305.2008.00228.x","article-title":"Low-dose theophylline reduces symptoms of acute mountain sickness","volume":"15","author":"K\u00fcpper TE","year":"2008","unstructured":"K\u00fcpper TE, Strohl KP, Hoefer M, Gieseler U, Netzer CM, Netzer NC. Low-dose theophylline reduces symptoms of acute mountain sickness. J Travel Med. 2008, 15:307-14. 10.1111\/j.1708-8305.2008.00228.x","journal-title":"J Travel Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2011.1005","article-title":"Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial","volume":"12","author":"Talbot NP","year":"2011","unstructured":"Talbot NP, Smith TG, Privat C, et al.. Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt Med Biol. 2011, 12:265-9. 10.1089\/ham.2011.1005","journal-title":"High Alt Med Biol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.3.8087361","article-title":"Nifedipine does not prevent acute mountain sickness","volume":"150","author":"Hohenhaus E","year":"1994","unstructured":"Hohenhaus E, Niroomand F, Goerre S, Vock P, Oelz O, B\u00e4rtsch P. Nifedipine does not prevent acute mountain sickness. Am J Respir Crit Care Med. 1994, 150:857-60. 10.1164\/ajrccm.150.3.8087361","journal-title":"Am J Respir Crit Care Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2007.1052","article-title":"Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia","volume":"8","author":"Luks AM","year":"2007","unstructured":"Luks AM, Henderson WR, Swenson ER. Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia. High Alt Med Biol. 2007, 8:131-8. 10.1089\/ham.2007.1052","journal-title":"High Alt Med Biol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.3.416","article-title":"Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial","volume":"29","author":"Heo K","year":"2014","unstructured":"Heo K, Kang JK, Choi CM, Lee MS, Noh KW, Kim SB. Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial. J Korean Med Sci. 2014, 29:416-22. 10.3346\/jkms.2014.29.3.416","journal-title":"J Korean Med Sci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1089\/152702903321488979","article-title":"Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial","volume":"4","author":"Basnyat B","year":"2003","unstructured":"Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol. 2003, 4:45-52. 10.1089\/152702903321488979","journal-title":"High Alt Med Biol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1580\/06-WEME-OR-062R2.1","article-title":"Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollag\u00fce (3696 m) in northern Chile","volume":"18","author":"Moraga FA","year":"2007","unstructured":"Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollag\u00fce (3696 m) in northern Chile. Wilderness Environ Med. 2007, 18:251-7. 10.1580\/06-WEME-OR-062R2.1","journal-title":"Wilderness Environ Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226699","article-title":"Effects of acute exposure and acclimatization to high-altitude on oxygen saturation and related cardiorespiratory fitness in health and disease","volume":"11","author":"Furian M","year":"2022","unstructured":"Furian M, Tannheimer M, Burtscher M. Effects of acute exposure and acclimatization to high-altitude on oxygen saturation and related cardiorespiratory fitness in health and disease. J Clin Med. 2022, 11:6699. 10.3390\/jcm11226699","journal-title":"J Clin Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1089\/152702904322963672","article-title":"A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m)","volume":"5","author":"Carlsten C","year":"2004","unstructured":"Carlsten C, Swenson ER, Ruoss S. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol. 2004, 5:33-9. 10.1089\/152702904322963672","journal-title":"High Alt Med Biol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.wem.2010.06.009","article-title":"Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT)","volume":"21","author":"Gertsch JH","year":"2010","unstructured":"Gertsch JH, Lipman GS, Holck PS, et al.. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med. 2010, 21:236-43. 10.1016\/j.wem.2010.06.009","journal-title":"Wilderness Environ Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109003","article-title":"Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment: a randomized double-blinded placebo-controlled clinical trial","volume":"116","author":"Yang J","year":"2019","unstructured":"Yang J, Zhang L, Liu C, et al.. Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment: a randomized double-blinded placebo-controlled clinical trial. Biomed Pharmacother. 2019, 116:109003. 10.1016\/j.biopha.2019.109003","journal-title":"Biomed Pharmacother"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00707","article-title":"Changes in subendocardial viability ratio with acute high-altitude exposure and protective role of acetazolamide","volume":"61","author":"Salvi P","year":"2013","unstructured":"Salvi P, Revera M, Faini A, et al.. Changes in subendocardial viability ratio with acute high-altitude exposure and protective role of acetazolamide. Hypertension. 2013, 61:793-9. 10.1161\/HYPERTENSIONAHA.111.00707","journal-title":"Hypertension"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316653867","article-title":"Budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme upon high-altitude exposure","volume":"17","author":"Li HJ","year":"2016","unstructured":"Li HJ, Zheng CR, Chen GZ, et al.. Budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme upon high-altitude exposure. J Renin Angiotensin Aldosterone Syst. 2016, 17:1470320316653867. 10.1177\/1470320316653867","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251805","article-title":"Prevention of high-altitude pulmonary edema by nifedipine","volume":"325","author":"B\u00e4rtsch P","year":"1991","unstructured":"B\u00e4rtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med. 1991, 325:1284-9. 10.1056\/NEJM199110313251805","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-7-200610030-00007","article-title":"Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial","volume":"145","author":"Maggiorini M","year":"2006","unstructured":"Maggiorini M, Brunner-La Rocca HP, Peth S, et al.. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006, 145:497-506. 10.7326\/0003-4819-145-7-200610030-00007","journal-title":"Ann Intern Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2008.1066","article-title":"Acetazolamide fails to decrease the incidence of acute mountain sickness: a pilot study","volume":"9","author":"Basnyat B","year":"2008","unstructured":"Basnyat B, Holck PS, Pun M, et al.. Acetazolamide fails to decrease the incidence of acute mountain sickness: a pilot study. High Alt Med Biol. 2008, 9:315-9. 10.1089\/ham.2008.1066","journal-title":"High Alt Med Biol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2011.0007","article-title":"Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial","volume":"12","author":"Bates MG","year":"2011","unstructured":"Bates MG, Thompson AA, Baillie JK, Sutherland AI, Irving JB, Hirani N, Webb DJ. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. High Alt Med Biol. 2011, 12:207-14. 10.1089\/ham.2011.0007","journal-title":"High Alt Med Biol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2018.0143","article-title":"Physiological responses in humans acutely exposed to high altitude (3480\u2009m): minute ventilation and oxygenation are predictive for the development of acute mountain sickness","volume":"20","author":"Burtscher M","year":"2019","unstructured":"Burtscher M, Philadelphy M, Gatterer H, Burtscher J, Faulhaber M, Nachbauer W, Likar R. Physiological responses in humans acutely exposed to high altitude (3480\u2009m): minute ventilation and oxygenation are predictive for the development of acute mountain sickness. High Alt Med Biol. 2019, 20:192-7. 10.1089\/ham.2018.0143","journal-title":"High Alt Med Biol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1274111","article-title":"Effect of altitude and acetazolamide on postural control in healthy lowlanders 40\u00a0years of age or older. Randomized, placebo-controlled trial","volume":"14","author":"Mutschler T","year":"2023","unstructured":"Mutschler T, Furian M, Lichtblau M, et al.. Effect of altitude and acetazolamide on postural control in healthy lowlanders 40\u00a0years of age or older. Randomized, placebo-controlled trial. Front Physiol. 2023, 14:1274111. 10.3389\/fphys.2023.1274111","journal-title":"Front Physiol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011788","article-title":"The effects of respiratory inhaled drugs on the prevention of acute mountain sickness","volume":"97","author":"Wang X","year":"2018","unstructured":"Wang X, Chen H, Li R, Fu W, Yao C. The effects of respiratory inhaled drugs on the prevention of acute mountain sickness. Medicine (Baltimore). 2018, 97:e11788. 10.1097\/MD.0000000000011788","journal-title":"Medicine (Baltimore)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7359-2_18","article-title":"Carbonic anhydrase inhibitors and high altitude illnesses","volume":"75","author":"Swenson ER","year":"2014","unstructured":"Swenson ER. Carbonic anhydrase inhibitors and high altitude illnesses. Subcell Biochem. 2014, 75:361-86. 10.1007\/978-94-007-7359-2_18","journal-title":"Subcell Biochem"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00348-6","article-title":"Acetazolamide modulates intracranial pressure directly by its action on the cerebrospinal fluid secretion apparatus","volume":"19","author":"Barbuskaite D","year":"2022","unstructured":"Barbuskaite D, Oernbo EK, Wardman JH, et al.. Acetazolamide modulates intracranial pressure directly by its action on the cerebrospinal fluid secretion apparatus. Fluids Barriers CNS. 2022, 19:53. 10.1186\/s12987-022-00348-6","journal-title":"Fluids Barriers CNS"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1988.64.4.1445","article-title":"Ventilatory response to sustained hypoxia after pretreatment with aminophylline","volume":"64","author":"Easton PA","year":"1988","unstructured":"Easton PA, Anthonisen NR. Ventilatory response to sustained hypoxia after pretreatment with aminophylline. J Appl Physiol (1985). 1988, 64:1445-50. 10.1152\/jappl.1988.64.4.1445","journal-title":"J Appl Physiol (1985)"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.wem.2023.05.013","article-title":"Wilderness Medical Society clinical practice guidelines for the prevention, diagnosis, and treatment of acute altitude illness: 2024 update","volume":"35","author":"Luks AM","year":"2024","unstructured":"Luks AM, Beidleman BA, Freer L, et al.. Wilderness Medical Society clinical practice guidelines for the prevention, diagnosis, and treatment of acute altitude illness: 2024 update. Wilderness Environ Med. 2024, 35:2S-19S. 10.1016\/j.wem.2023.05.013","journal-title":"Wilderness Environ Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.12.022","article-title":"Efficacy of acetazolamide for the prophylaxis of acute mountain sickness: a systematic review, meta-analysis and trial sequential analysis of randomized clinical trials","volume":"361","author":"Gao D","year":"2021","unstructured":"Gao D, Wang Y, Zhang R, Zhang Y. Efficacy of acetazolamide for the prophylaxis of acute mountain sickness: a systematic review, meta-analysis and trial sequential analysis of randomized clinical trials. Am J Med Sci. 2021, 361:635-45. 10.1016\/j.amjms.2020.12.022","journal-title":"Am J Med Sci"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2025.102868","article-title":"Comparative effects of pharmacological interventions for the prevention of acute mountain sickness: a systematic review and Bayesian network meta-analysis","volume":"66","author":"Wang J","year":"2025","unstructured":"Wang J, Lian N, Tang K, Deng Y, Li T. Comparative effects of pharmacological interventions for the prevention of acute mountain sickness: a systematic review and Bayesian network meta-analysis. Travel Med Infect Dis. 2025, 66:102868. 10.1016\/j.tmaid.2025.102868","journal-title":"Travel Med Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502144-evaluation-of-the-efficacy-of-pharmacological-interventions-in-the-prevention-of-acute-mountain-sickness-a-network-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:53:17Z","timestamp":1782798797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502144-evaluation-of-the-efficacy-of-pharmacological-interventions-in-the-prevention-of-acute-mountain-sickness-a-network-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":77,"URL":"https:\/\/doi.org\/10.7759\/cureus.111777","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}